ON1231320是一种选择性 PLK2 抑制剂，具有显著的抗肿瘤活性。它在癌症研究和治疗中表现出了良好的应用前景。

HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.

Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole/centrosome assembly.

3MB-PP1是一种嘌呤类似物，是一种 Polo 样激酶 1 (Plk1) 抑制剂。靶向突变的 Plk1 等位基因，阻断细胞有丝分裂。其特异性抑制 Cdk8 及 ZIPK 激酶的活性，常用于研究细胞分裂和白色念珠菌感染的机制。

Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.

CFI400945 is a potent and selective,orally bioavailable PLK4 inhibitor with an IC50 value of 2.8 ±1.4 nM have potential antineoplastic activity.

CFI-400437 is a selective ATP-competitive PLK4 inhibitor with IC50 value of 1.55nM.

Rigosertib Sodium (Random Configuration) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3.

SBE13 HCl is a potent and selective PLK1 inhibitor with IC50 of 0.2 nM while 875 nM and 66 μM for PLK3 and PLK2. SBE 13 could also induce cell cycle arrest, reduce cell proliferation with EC50 of 5-60 µM, and induce apoptosis in a broad range of human cancer cell lines.

NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor (IC50=2 nM) with potential antineoplastic activity and no inhibition on PLK2 and PLK3.

GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM (PLK1) and 9.1 nM (PLK3) and displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2.

Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM and shows 30-fold greater selectivity against PLK2 and no activity to PLK3.

GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.

TAK-960 is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).

C6 Ceramide是一种神经酰胺途径的激活剂，对多种癌细胞系具有活性，并可作为化疗药物的佐剂以增强抗肿瘤作用。

Volasertib（BI 6727）是一种口服活性、高效和ATP竞争性的Polo样激酶1（PLK1）抑制剂，IC50为0.87 nM。它抑制PLK2和PLK3，IC50值分别为5 nM和56 nM，诱导有丝分裂停滞和凋亡。Volasertib是一种二氢蝶啶酮衍生物，在多种癌症模型中表现出显著的抗肿瘤活性。

LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 μM and also inhibits PLK3 with IC50 of 7.2 μM.

ONO-4059 is a selective inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.